Prospective Feasibility Study of Cell Free Circulating Tumor DNA for the Diagnosis and Treatment Monitoring in Early-stage Non-small Cell Lung Cancer
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
The aim of the study is to evaluate whether peripheral circulating cell-free tumor DNA (cfDNA) can aid screening of recurrence after complete resection of early stage non-small cell lung cancer.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 90
Healthy Volunteers: f
View:
• All subjects need to sign the informed consent form
• All subjects have Non-small cell lung cancer which suspected on chest CT or confirmed pathologically preoperatively.
• Non-small cell lung cancer have to confirmed pathologically after operation
• Clinical stage I - IIIA by AJCC 7th staging system
Locations
Other Locations
Republic of Korea
Samsung Medical Center
RECRUITING
Seoul
Contact Information
Primary
Jhingook Kim, MD
jkimsmc@skku.edu
+82-2-3410-3483
Time Frame
Start Date: 2017-08-28
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 700
Related Therapeutic Areas
Sponsors
Collaborators: Guardant Health, Inc.
Leads: Samsung Medical Center